Toronto, ON April 4, 2003 ChondroGene announced today that Dr Frank Barry has been appointed to its scientific advisory board. Dr Barry has been working in the field of osteoarthritis (OA) research for the past 20 years in both academic and commercial environments, and most recently as director, arthritis research at Osiris Therapeutics.
Dr Barry received a BSc, MSc and PhD in biochemistry from the National University of Ireland, University College, Cork. He has also held a variety of teaching positions including lecturer in biochemistry at University College Cork, assistant professor, department of biochemistry and molecular biology, University of South Florida College of Medicine. He has also been lecturer at John Hopkins University in the graduate program in biotechnology. He has over 60 publications in osteoarthritis and related areas along with over 30 invited papers and presentations in various OA publications and meetings.
“ChondroGene is very fortunate to have Dr Barry join our scientific advisory board. Frank has been a leader in the development of new scientific approaches for treating isolated cartilage defects,” says Dr K Wayne Marshall, President and CEO of ChondroGene. "We share the view that the lessons learned in treating cartilage defects will ultimately contribute to new breakthroughs in the local treatment of OA. Frank’s experience and vision in this area will enable him to make important contributions to ChondroGene’s biomarker and therapeutic programs focussed on delivering novel products for diagnosing and treating OA.”
ChondroGene is a genomics-based company focused on the discovery and development of disease-specific therapeutic and diagnostic products, specializing in osteoarthritis.